In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maureen Kenny

Executive Editor

London, UK
Maureen's expertise in bringing exclusive, business-critical content to the expanded Pink Sheet audience builds upon her many years' experience as an editor and reporter. Most recently, Maureen headed Scrip Regulatory Affairs, an indispensable publication for both pharmaceutical and medtech regulatory affairs professionals worldwide. She managed the publication's move from print to digital. Previous leadership roles also include being editor of Clinica Medtech Intelligence and acting editor of Scrip Intelligence. She chaired the DIA EuroMeeting plenary session in Paris in April 2015 and spent two years in New York covering the pharmaceutical industry in the US, Canada and, being a fluent Spanish speaker, Latin America. Maureen is based in London.
Advertisement
Set Alert for Articles By Maureen Kenny

Latest From Maureen Kenny

GW Pharma Looks Forward To EU Epidyolex Launch

Anticipating pan-EU approval of Epidyolex within the next six months, GW Pharmaceuticals is gearing up to launch what would be the first plant-derived cannabinoid medicine to be approved under the EU centralized procedure.

Companies Neurology

EU Accelerated Assessment Tracker

Accelerated assessment requests at the European Medicines Agency.

Review Pathway Europe

EU Accelerated Assessment Tracker 2018: Rejection Rates Remain High

The European Medicines Agency will fast-track Shionogi’s new antibiotic, cefiderocol, through regulatory review when the company files for approval but there’s no special treatment for Roche’s new tissue agnostic oncologic, entrectinib. More than half the accelerated assessment requests made in 2018 to the EMA failed to make the grade.

Europe BioPharmaceutical

EU Cross-Country Coalition Targets New Products For Joint Pricing Talks

The BeNeLuxAI initiative was among the many topics covered at the DIA Europe 2019 conference in Austria last week. The cross-country coalition has some new drugs in its sights for joint pricing talks and the conference was given an insight into the workings of the collaboration by a Belgian health department advisor close to the initiative.

Health Technology Assessment Pricing Debate

EU Big Data Report Takeaways Ready ‘In Weeks’

EU regulators have been working on a project to help determine the potential role of big data in medicines assessment for almost two years. They will soon be ready to release their keenly awaited conclusions.

Europe Regulation

EU Accelerated Assessment Tracker: Nine Definites So Far From 24 Requests In 2018

In 2018, the European Medicines Agency considered 24 requests from drug companies for fast-track review of their planned marketing authorization applications. The agency has granted at least nine requests, eleven have been rejected and the results of four have yet to be disclosed.

Europe Review Pathway
See All
Advertisement
UsernamePublicRestriction

Register